Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era.

Abuelgasim, Khadega A; Ghazi, Samer; Alahmari, Bader; Alhejazi, Ayman; Alaskar, Ahmed; Alzahrani, Mohsen; Damlaj, Moussab

Abuelgasim, Khadega A; Ghazi, Samer; Alahmari, Bader; Alhejazi, Ayman; Alaskar, Ahmed; Alzahrani, Mohsen; Damlaj, Moussab.

Afiliação

Abuelgasim KA; Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Ghazi S; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Alahmari B; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Alhejazi A; Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Alaskar A; Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Alzahrani M; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Damlaj M; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

Leuk Res Rep ; 16: 100276, 2021.

Article em En | MEDLINE | ID: mdl-34804792